TW202339758A - 藉由週期性遏制醛固酮合酶治療高血壓之方法 - Google Patents

藉由週期性遏制醛固酮合酶治療高血壓之方法 Download PDF

Info

Publication number
TW202339758A
TW202339758A TW112102537A TW112102537A TW202339758A TW 202339758 A TW202339758 A TW 202339758A TW 112102537 A TW112102537 A TW 112102537A TW 112102537 A TW112102537 A TW 112102537A TW 202339758 A TW202339758 A TW 202339758A
Authority
TW
Taiwan
Prior art keywords
individual
cyp
hypertensive
hydroxylase inhibitor
serum
Prior art date
Application number
TW112102537A
Other languages
English (en)
Chinese (zh)
Inventor
大衛 羅德曼
布萊恩 泰勒 斯玲斯比
喬恩 康格爾頓
清水秀俊
大田吉安
織橋窗里
Original Assignee
美商礦物質醫療股份有限公司
日商田邊三菱製藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商礦物質醫療股份有限公司, 日商田邊三菱製藥股份有限公司 filed Critical 美商礦物質醫療股份有限公司
Publication of TW202339758A publication Critical patent/TW202339758A/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW112102537A 2022-01-19 2023-01-19 藉由週期性遏制醛固酮合酶治療高血壓之方法 TW202339758A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US202263300967P 2022-01-19 2022-01-19
US63/300,967 2022-01-19
US202263400301P 2022-08-23 2022-08-23
US63/400,301 2022-08-23

Publications (1)

Publication Number Publication Date
TW202339758A true TW202339758A (zh) 2023-10-16

Family

ID=87347916

Family Applications (1)

Application Number Title Priority Date Filing Date
TW112102537A TW202339758A (zh) 2022-01-19 2023-01-19 藉由週期性遏制醛固酮合酶治療高血壓之方法

Country Status (7)

Country Link
US (1) US20250099475A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466021A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025503015A (cg-RX-API-DMAC7.html)
KR (1) KR20240140102A (cg-RX-API-DMAC7.html)
CA (1) CA3240577A1 (cg-RX-API-DMAC7.html)
TW (1) TW202339758A (cg-RX-API-DMAC7.html)
WO (1) WO2023139506A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4577217A4 (en) * 2022-08-23 2026-08-12 Mineralys Therapeutics Inc METHODS OF TREATING HYPERTENSION WITH A COMBINATION OF AN ALDOSTERONE SYNTHASE INHIBITOR AND A DIURETIC
KR20250053914A (ko) * 2022-08-23 2025-04-22 미네랄리스 테라퓨틱스, 아이엔씨. 비만 대상체에서 고혈압을 치료하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9550750B2 (en) * 2012-10-05 2017-01-24 Merck Sharp & Dohme Corp. Indoline compounds as aldosterone synthase inhibitors
WO2014179186A1 (en) * 2013-04-30 2014-11-06 Boehringer Ingelheim International Gmbh Aldosterone synthase inhibitors
MY176401A (en) * 2014-04-24 2020-08-05 Mitsubishi Tanabe Pharma Corp Novel disubstituted 1,2,4-triazine compound
US20240009201A1 (en) * 2020-10-26 2024-01-11 Mineralys Therapeutics, Inc. Cyp11b2 beta hydroxylase inhibitors for hypertension

Also Published As

Publication number Publication date
KR20240140102A (ko) 2024-09-24
EP4466021A1 (en) 2024-11-27
WO2023139506A1 (en) 2023-07-27
CA3240577A1 (en) 2023-07-27
US20250099475A1 (en) 2025-03-27
JP2025503015A (ja) 2025-01-30
EP4466021A4 (en) 2026-01-14

Similar Documents

Publication Publication Date Title
Lakkis et al. RAAS escape: a real clinical entity that may be important in the progression of cardiovascular and renal disease
US9216221B2 (en) Medicament and method of diagnosis for treating subclinical Cushing's syndrome
US20250099475A1 (en) Methods of treating hypertension by periodic suppression of aldosterone synthase
JP2023546970A (ja) 高血圧のためのcyp11b2ベータヒドロキシラーゼ阻害剤
Glicklich et al. Drug therapy of apparent treatment-resistant hypertension: focus on mineralocorticoid receptor antagonists
Morganti et al. Aliskiren: the first direct renin inhibitor available for clinical use
TWI888340B (zh) 用於預防或治療貓之全身性疾病之血管收縮素ii受體拮抗劑
Tani et al. Effects of the T/L-type calcium channel blocker benidipine on albuminuria and plasma aldosterone concentration a pilot study involving switching from L-type calcium channel blockers to Benidipine
JP6934859B2 (ja) 腎疾患の治療のための医薬
US20260053811A1 (en) Methods of treating hypertension in obese subjects
US20260053812A1 (en) Methods of treating hypertension with a combination of an aldosterone synthase inhibitor and a diuretic
TW202519234A (zh) 以洛倫德羅斯塔(lorundrostat)及二或多種降血壓藥物之組合治療高血壓之方法
Elliott et al. Pharmacology of antihypertensive drugs
TW202510887A (zh) 以勞倫卓司他(lorundrostat)或勞倫卓司他與sglt2抑制劑之組合治療慢性腎臟病(ckd)或ckd與高血壓之方法
GB2503396A (en) Treatment of subclinical Cushing's syndrome and/or incidentaloma
EA044411B1 (ru) Антагонист рецептора ангиотензина ii для предотвращения или лечения системных заболеваний у котов
EP1842543A1 (en) Pharmaceutical composition coprising an aldosterone synthase inhibitor and a mineralcorticoid receptor antagonist
奥田哲 et al. Effect of angiotensin-converting enzyme inhibitor/calcium antagonist combination therapy on renal function in hypertensive patients with chronic kidney disease: Chikushi Anti-hypertension Trial–Benidipine and Perindopril (CHAT-BP)